Work

Peptide-based LDH5 inhibitors enter cancer cells and impair proliferation

Year: 2022

Type: article

Source: Cellular and Molecular Life Sciences

DOI: 10.1007/s00018-022-04633-3

Authors: Ferran Nadal-Bufí, Lai Y. Chan, Hadi H. Mohammad, Jody M. Mason, Carlos Salomon, Andrew Lai, Erik W. Thompson, David J. Craik, Quentin Kaas, Sónia T. Henriques

Institutions: Translational Research Institute, Queensland University of Technology, The University of Queensland, ARC Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, Knowledge University, University of Bath, Royal Brisbane and Women's Hospital, Universidad del Alba

Language: English

Topic: Cancer, Hypoxia, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Ovarian Cancer Research Foundation, Cancer Research UK, Queensland University of Technology, Biotechnology and Biological Sciences Research Council, Australian Research Council, National Health and Medical Research Council, Medical Research Future Fund

Awards: Ovarian cancer early detection, monitoring and therapeutic intervention using extracellular vesicles, G2299875942, ARC Centre of Excellence for Innovations in Peptide and Protein Science, Developing new therapeutic targets and identifying biomarkers for gestational diabetes and ovarian cancer using extracellular vesicles, From Peptides to Mimetics: Towards Smaller More Stable Drug-like Protein-protein Interaction Inhibitors, G4760630197, A Generalised Approach to Derive Functionally Active Peptide Inhibitors of Transcription Factor Activity, Taking Australia from the farm to the pharm, Breaching membrane barriers, G8609205739

OpenAlex ID: W4310276579

FWCI: 1.47

Cites: 92

Cited by: 16

Related to: 10